LyphoMed's aerosol pentamidine
Clinical trials for treatment of Pneumocytis carinii pneumonia (PCP) now have 30-40 patients in five New York area centers and are continuing to recruit more subjects. The company announced in an Aug. 31 press release that the five hospitals involved in the studies are seeking patients to enter the non-placebo controlled double blind studies in which each patient receives either aerosolized pentamidine or trimethoprim sulphamethoxazole (TMP/SMX) intravenously or orally. LyphoMed has ongoing studies for treatment and prophylaxis of PCP in centers nationwide, and has recently begun clinical studies for pediatriac applications of aerosol Pentam in one independent center and at the National Institutes for Allergy and Infectious Diseases.
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.